Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibiotics Need REMS For Public, Not Patient, Safety Reasons, IDSA Says

Executive Summary

Overuse of antibiotics could be controlled using elements of FDA’s Risk Evaluation and Mitigation Strategies, the Infectious Diseases Society of America argues in an upcoming position paper.

You may also be interested in...



Antibiotic Development Incentives Could GAIN Support From Pipeline Survey

A survey showing improvement in the pipeline for new antibiotics could further the growing momentum for legislation that would create more development incentives.

Antibiotic Development Incentives Could GAIN Support From Pipeline Survey

A survey showing improvement in the pipeline for new antibiotics could further the growing momentum for legislation that would create more development incentives.

NICE-Style Value-Based Pricing Might Actually Boost Antibiotic Sales In U.S.

Antibiotic development could expand if the U.S. adopted a system to evaluate the drugs’ effectiveness and value to society for reimbursement purposes, similar to that of the British National Institute for Health and Clinical Excellence, according to an article in the Sept. 7 issue of the journal Health Affairs.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS052596

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel